What is the 'gas station gummies' problem in the functional mushroom industry?

The 'gas station gummies' problem refers to unregulated psychoactive products sold in smoke shops and gas stations that are marketed as Amanita muscaria or other functional mushroom products — but actually contain undisclosed research chemical tryptamine analogues, synthetic benzodiazepines, pregabalin (Lyrica), or ketamine analogues. Christian Rasmussen of Amanara, who witnessed this problem emerge in real-time, reported that beginning in 2022, manufacturers who initially approached Amanita muscaria as 'the next delta-8' switched to research chemical tryptamines when Amanita didn't provide the effects they wanted. The products remained on shelves labeled as Amanita products while containing entirely different compounds. This mislabeling crisis has resulted in consumer deaths — with individuals dying from products whose actual contents were unknown.

Why is testing Amanita muscaria products technically challenging?

Amanita muscaria compliance faces unique technical obstacles: the two primary active compounds — ibotenic acid and muscimol — are both notoriously unstable small molecules. Their instability makes them difficult to quantify accurately, and they elute before the injection peak in standard chromatography graphs, complicating standard analytical methods. Additionally, the research chemical adulterants being substituted in fraudulent products are often so new that the FDA has not yet established standardized testing methods for them. As Rasmussen explained, manufacturers 'just keep pumping new ones out,' meaning the compound to be tested is often identified only after a product has already reached consumers.

What is the difference between mushroom fruiting bodies and mycelium for labeling compliance?

FDA guidelines require that supplement labels accurately distinguish between mushroom fruiting bodies and mycelium — two biologically distinct materials with different bioactive compound profiles. Fruiting bodies are the above-ground reproductive structures of the mushroom and typically contain higher concentrations of beta-glucans and other bioactive compounds. Mycelium is the root-like vegetative structure, often grown on grain substrate, which may have a significantly different nutrient and bioactive profile. Labels cannot imply fruiting body content when a product contains only mycelium, and brands making beta-glucan potency claims must verify those claims against the specific material in their product. Misrepresenting mycelium as mushroom fruiting body content constitutes misbranding under FDA regulations.

How does blockchain technology solve the product-switching fraud problem in mushroom supply chains?

A common fraud scheme in the supplement supply chain involves altering lab reports after the original testing is complete — so a brand's legitimate COA from a clean product gets modified to cover a substituted or adulterated product further down the distribution chain. Blockchain solves this by recording each lab result as an immutable, cryptographically verified entry at the point of origin. Qredible's Q-Trust platform connects directly to laboratories so results are anchored to the blockchain before they ever reach manufacturers or distributors — meaning any subsequent modification is mathematically detectable. As Fitzpatrick explained, financial services partners are increasingly requiring product registration in blockchain systems as a condition for providing payment processing to functional mushroom and other regulated wellness brands.

Why does mushroom product compliance affect payment processing access?

Payment processors and acquiring banks evaluate the entire risk profile of a merchant's category, not just individual businesses within it. When a product category becomes associated with consumer harm, fraud, and regulatory enforcement — as functional mushrooms are increasingly becoming due to bad actors — processors apply broad restrictions affecting compliant businesses alongside fraudulent ones. Rasmussen confirmed this from personal experience, noting payment processing disruptions despite operating ethically. Fitzpatrick warned that without documented compliance infrastructure, brands face a cash-only distribution model that makes it 'nearly impossible to scale.' Q-Certification's verified compliance credential directly addresses this by providing payment processors with third-party-verified, continuously monitored compliance status that distinguishes ethical operators from the broader high-risk category.

How does the functional mushroom industry's situation parallel the hemp and CBD industry's history?

Fitzpatrick drew a direct parallel on the Qredible Live broadcast: the hemp and CBD industry suffered widespread payment processing exclusions and regulatory backlash after bad actors created products designed to look like popular candy brands while containing THC and other compounds — taking advantage of legislative gray areas before enforcement frameworks caught up. The entire industry was 'painted with that broad brush,' causing lasting harm to legitimate businesses still working to recover their market standing. The functional mushroom industry is following the same trajectory: legitimate operators with rigorous testing and transparent labeling are being affected by the market contamination from gas station gummy manufacturers, resulting in platform bans, payment processing disruptions, and growing regulatory scrutiny. The lesson from hemp is that proactive compliance infrastructure built before enforcement arrives is far less costly than reactive rebuilding after industry-wide crackdowns.

Why Mushroom Product Compliance Matters

Author: The Qredible Team

Date: November 25, 2025

A single mislabeled product can destroy years of scientific research, erode consumer trust, and shut down legitimate businesses overnight. In the functional mushroom industry, this isn't a hypothetical concern—it's happening right now, with deadly consequences. The question facing ethical business owners is simple: How do you protect your brand and your customers when bad actors flood the market with dangerous, mislabeled products?

During a recent Qredible Live Broadcast, Christian Rasmussen, founder of Amanara (formerly Minnesota Nice Ethnobotanicals), shared critical insights on mushroom product compliance and the urgent need for quality control in the functional wellness industry. This discussion with Brian Fitzpatrick, CEO of Qredible, highlighted the parallels between the challenges facing the mushroom industry and those that nearly destroyed the hemp and CBD markets, and why transparency and rigorous testing are essential for long-term business success.

The "Gas Station Gummies" Problem

The mushroom product compliance crisis mirrors what happened in the hemp industry when unscrupulous manufacturers began creating products that looked like popular candy brands but contained THC and other compounds. Rasmussen witnessed this problem emerge in real-time as his industry gained visibility.

"We see what we call them gas station gummies and they're pushed by these big companies that have products in smoke shops all around the countries or in gas stations," Rasmussen explained. These companies approached him in 2022, viewing Amanita muscaria as "the next delta-8," a THC alternative commonly found in smoke shops.

The situation quickly deteriorated when these manufacturers realized Amanita muscaria wouldn't provide the effects they wanted. "They all started switching to research chemical tryptamine," Rasmussen revealed. These tryptamines—psychedelic analogues of psilocybin including compounds like LSD and DMT—exist in a legal gray area but present serious safety concerns.

The Deadly Consequences of Mislabeling

What makes this mushroom product compliance failure particularly dangerous is the deceptive marketing. "You have products in every single smoke shop around the country, lots of gas stations that state that it has Amanita in it, but in fact in reality it's 4-aco-DMT, one of these other research chemical tryptamine analogues," Rasmussen said.

The contents of these mislabeled products have included far more than psychedelics. "In the early days we saw research chemical benzodiazepines in them which are extraordinarily addicting and dangerous. We saw pregabalin which is Lyrica. We saw ketamine analogues. We saw a whole bunch of things that were being put in these gummies marketed as Amanita products."

The consequences turned fatal. "Last year, an individual, a few individuals died from one of these products, one of these brands," Rasmussen reported. "And who knows what actually killed them."

The Testing Challenge

Establishing effective mushroom product compliance faces unique technical challenges. As Rasmussen explained, "The two compounds in Amanita, the two main compounds are both notoriously very unstable. They're very small molecules, so they're hard to quantify and then they elude before the injection peak in the graphs."

This technical complexity makes accurate testing difficult, which Rasmussen acknowledged "makes the compliance aspect of this very tricky as far as gauging potency or quality of the products." The problem is compounded by the constantly changing landscape of research chemicals being used in fraudulent products.

"These like the FDA, there aren't standards to test a lot of these compounds. They're so new, they just keep pumping new ones out. So, you never really know what you're getting," he noted. This creates a significant gap in mushroom product compliance infrastructure that legitimate businesses must work to address.

Learn from the Hemp Industry's Mistakes

Fitzpatrick drew direct parallels between the mushroom industry's current challenges and what happened to hemp and CBD businesses. "We saw that side was some bad actors doing some bad things which ruined a lot for a lot of the good players out there that were creating some great products," he observed.

The hemp industry's problems stemmed from manufacturers who "took advantage of some legislation. They started marketing to products that look like a bag of Skittles." The result? "The industry got painted with that broad brush and it hurt a lot of companies that they're trying to dig out of."

Fitzpatrick emphasized that the solution requires "science-driven product development, robust consumer education, and basically transparency of product tracking." Without these elements, even ethical businesses struggle to maintain payment processing and banking relationships.

The Role of Blockchain in Product Verification

One solution Qredible developed specifically addresses the product switching problem that plagues mushroom product compliance efforts. "I created very early on was a blockchain solution through Qredible to connect directly to the labs and to for those labs lab reports to be looked at by the distributors and manufacturers and viewed and then distributed through the chain through the blockchain," Fitzpatrick explained.

This technology prevents a common fraud scheme: "Your lab report that you feel good about can get changed down the line." By recording lab results on a blockchain, they become immutable and verifiable throughout the supply chain.

The financial services industry has recognized the value of this approach. "The financial services groups are coming back up through Qredible now and saying, 'Look, we're only going to trust it if your product's registered in this blockchain in the Qredible bio,'" Fitzpatrick noted.

Why Compliance Equals Access

For businesses in the functional mushroom space, mushroom product compliance isn't just about following rules. It's about survival. Without proper compliance frameworks, companies lose access to essential financial services.

"If you don't have that, nobody can buy your product, right? You're going to end up selling it in a dispensary type model where it's all cash," Fitzpatrick warned. This cash-only model severely limits growth potential and makes it nearly impossible to scale ethical businesses.

Rasmussen confirmed these challenges from personal experience: "We get banned from Instagram all the time like they'll just shut us down for no reason because they just don't like the products that we're working with. And similarly, you know like credit card processing of course we've had our issues with that."

What Ethical Manufacturers Can Do Now

While waiting for comprehensive regulatory frameworks, ethical businesses can take immediate action to demonstrate their commitment to mushroom product compliance. Rasmussen outlined his approach: "What I can really do right now in the moment is consistently educate and bring our community together to create a louder and louder and louder voice."

He emphasized the importance of alliance-building: "Get us and the other few players that are doing this ethically and properly like more recognition and more standing and more platform so that we can educate on a on a wider and wider scale."

Rasmussen also made his position on mislabeling clear: "I don't inherently have anything wrong with a psilocybin analog, but like you shouldn't be putting something out on the market and marketing it as something else. Like that seems like a pretty big red flag."

Protect Consumers and Build Industry Credibility

The functional mushroom industry stands at a crossroads. Without strong mushroom product compliance standards, bad actors will continue to endanger consumers and damage the reputation of legitimate businesses. As Fitzpatrick noted, "Nobody wants to see a good product like yours get adulterated down the line and get compromised. I mean, that's liability to you, but more importantly, it ruins the reputation of good companies like yours."

For businesses committed to quality and safety, the path forward requires investment in proper testing, transparent supply chain documentation, product registration systems like blockchain verification, and ongoing consumer education. As Rasmussen works to build research and regulatory frameworks, ethical manufacturers must also focus on "figuring out regulatory testing, testing bodies maybe for these types of products."

The stakes couldn't be higher. People's lives depend on accurate labeling and quality control in the functional wellness industry. By prioritizing mushroom product compliance today, ethical businesses can build the trust and infrastructure needed to make safe, effective products accessible to the thousands of people who need them—while protecting the industry from the devastating consequences of bad actors.